

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**To the Board of Directors of Bharat Parenterals Limited**


1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Bharat Parenterals Limited** ("the Company") for the quarter ended 30th June, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

UDIN: 20042005AAAALB3089


Alok Shah

Partner

Membership No. 042005

Date: 20th August, 2020

Place: Vadodara



Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**To the Board of Directors of Bharat Parenterals Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Bharat Parenterals Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2020 attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

4. The statement includes results of the following entities:
 - i. Varenym Healthcare Private Limited (Subsidiary)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations,



including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 280.18 lakhs, total net profit after tax of Rs. 25.44 Lakhs and total comprehensive profit of Rs. 25.44 Lakhs for the quarter ended 30th June, 2020. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For **CNK & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036

UDIN : 20042005AAAALC8148

Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 20th August, 2020

BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road, Karelibaug, Vadodara - 390 018

CIN:U24231GJ199ZPLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER 30th JUNE, 2020

Sr. No.	Particular	Quarter Ended			Rs. In Lakhs
		30.06.2020	31.03.2020	30.06.2019	Year Ended
		(Unaudited)	(Audited)	(Unaudited)	31.03.2020 (Audited)
1	A. Revenue from operations	5,393	5,391	4,937	22,633
	B. Other Income	250	205	327	1,148
	Total income	5,643	5,596	5,264	23,781
2	Expenses				
	A. Cost of materials consumed	3,414	3,526	2,375	13,073
	B. Purchase of Stock-in-Trade	44	250	976	1,977
	C. Changes in inventories of finished goods, work-in-progress and stock-in trade	129	(121)	(181)	(327)
	D. Employee benefit expense	347	351	347	1,411
	E. Finance costs	7	25	16	86
	F. Depreciation, depletion and amortisation expense	128	141	155	588
	G. Other Expenses	675	627	806	3,477
	Total expenses	4,743	4,798	4,493	20,286
3	Total profit before tax	900	799	770	3,495
4	Tax expense				
	Current tax	239	200	224	974
	Deferred tax	22	(186)	18	(117)
	Short / (Excess) provision of tax in respect of earlier years	-	1	-	8
	Total tax expenses	261	14	242	865
5	Net Profit / (loss) for period	638	785	528	2,630
6	Other comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurement of defined benefit obligation	1	14	(3)	5
	Income tax relating to Remeasurement of Defined benefit plans	(0)	(4)	1	(1)
	Other comprehensive Income for the year, net of taxes	1	10	(2)	4
7	Total Comprehensive Income for the period	639	795	526	2,634
8	Earnings per share				
	Basic (Rs.)	11.14	13.69	9.22	45.90
	Diluted (Rs.)	11.14	13.69	9.22	45.90

See accompanying notes to the Financial Results

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The Company has only one segment of activity, namely "Pharmaceuticals".
- The Company has during the quarter, disposed of its equity shareholding in Varenyam Healthcare Private Limited ("VHPL"). On such disposal, VHPL has ceased to be subsidiary of the company with effect from 30th June, 2020.
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, there is no significant impact on its financial results.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara
Date : 20th August, 2020



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road, Karelibaug, Vadodara - 390 018

CIN:U24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER 30th JUNE, 2020

Sr. No.	Particular	Quarter Ended			Rs. In Lakhs
		30.06.2020	31.03.2020	30.06.2019	Year Ended
		(Unaudited)	(Audited)	(Unaudited)	31.03.2020
1	A. Revenue from operations	5,491	5,477	4,961	22,818
	B. Other Income	250	206	327	1,148
	Total income	5,741	5,682	5,288	23,966
2	Expenses				
	A. Cost of materials consumed	3,414	3,526	2,375	13,073
	B. Purchase of Stock-in-Trade	75	309	1,015	2,115
	C. Changes in inventories of finished goods, work-in-progress and stock in-trade	121	(107)	(188)	(297)
	D. Employee benefit expense	383	393	380	1,558
	E. Finance costs	7	25	16	86
	F. Depreciation, depletion and amortisation expense	128	141	155	588
	G. Other Expenses	688	668	819	3,562
	Total expenses	4,816	4,955	4,571	20,686
3	Total profit before tax	925	727	717	3,280
4	Tax expense				
	Current tax	239	200	224	974
	Deferred tax	22	(186)	18	(117)
	Short / (Excess) provision of tax in respect of earlier years		1		8
	Total tax expenses	261	14	242	865
5	Net Profit / (loss) for period	664	713	475	2,414
6	Other comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurement of defined benefit obligation	1	14	(3)	5
	Income tax relating to Remeasurement of Defined benefit plans	(0)	(4)	1	(1)
	Other comprehensive Income for the year, net of taxes	1	10	(2)	4
7	Total Comprehensive Income for the period	665	723	473	2,418
8	Earnings per share				
	Basic (Rs.)	11.58	12.45	8.29	42.14
	Diluted (Rs.)	11.58	12.45	8.29	42.14

See accompanying notes to the Financial Results

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The Company has only one segment of activity, namely "Pharmaceuticals".
- The Company has during the quarter, disposed of its equity shareholding in Varenyam Healthcare Private Limited ("VHPL"). On such disposal, VHPL has ceased to be subsidiary of the company with effect from 30th June, 2020.
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, there is no significant impact on its financial results.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara
Date : 20th August, 2020

